Hans Guehring

1.9k total citations · 2 hit papers
53 papers, 1.5k citations indexed

About

Hans Guehring is a scholar working on Rheumatology, Surgery and Molecular Biology. According to data from OpenAlex, Hans Guehring has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Rheumatology, 16 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Hans Guehring's work include Osteoarthritis Treatment and Mechanisms (30 papers), Fibroblast Growth Factor Research (13 papers) and Knee injuries and reconstruction techniques (13 papers). Hans Guehring is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (30 papers), Fibroblast Growth Factor Research (13 papers) and Knee injuries and reconstruction techniques (13 papers). Hans Guehring collaborates with scholars based in Germany, United States and Denmark. Hans Guehring's co-authors include C. Ladel, Asger Reinstrup Bihlet, J.R. Andersen, M.A. Karsdal, Anne‐Christine Bay‐Jensen, M. Michaelis, F. Eckstein, Marc C. Hochberg, Renate Bang and Gabriele Sass and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Hans Guehring

51 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future

2016 274 citations M.A. Karsdal, M. Michaelis et al. Osteoarthritis and Cartilage profile →
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis

2019 242 citations Marc C. Hochberg, Hans Guehring et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans Guehring Germany	19	931	356	340	285	134	53	1.5k
Mohammed Sharif United Kingdom	23	1.3k 1.4×	533 1.5×	475 1.4×	366 1.3×	206 1.5×	54	2.0k
Cleo Bonnet United Kingdom	9	609 0.7×	310 0.9×	195 0.6×	249 0.9×	82 0.6×	13	1.0k
Anjing Liang China	24	366 0.4×	522 1.5×	340 1.0×	204 0.7×	114 0.9×	57	1.6k
Audrey Pigenet France	14	592 0.6×	265 0.7×	213 0.6×	204 0.7×	108 0.8×	25	1.0k
Yukio Akasaki Japan	21	592 0.6×	566 1.6×	570 1.7×	154 0.5×	97 0.7×	72	1.6k
Steeve Kwan Tat Canada	16	656 0.7×	742 2.1×	180 0.5×	264 0.9×	477 3.6×	18	1.5k
Anastasios Chanalaris United Kingdom	19	573 0.6×	424 1.2×	143 0.4×	214 0.8×	119 0.9×	37	1.2k
Giovanna Nalesso United Kingdom	15	710 0.8×	596 1.7×	138 0.4×	173 0.6×	133 1.0×	30	1.2k
Theodore C. Pellas United States	16	332 0.4×	253 0.7×	169 0.5×	170 0.6×	94 0.7×	23	1.0k
Moroe Beppu Japan	22	339 0.4×	394 1.1×	704 2.1×	259 0.9×	112 0.8×	64	1.6k

Countries citing papers authored by Hans Guehring

Since Specialization

Citations

This map shows the geographic impact of Hans Guehring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Guehring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Guehring more than expected).

Fields of papers citing papers by Hans Guehring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Guehring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Guehring. The network helps show where Hans Guehring may publish in the future.

Co-authorship network of co-authors of Hans Guehring

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Guehring. A scholar is included among the top collaborators of Hans Guehring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Guehring. Hans Guehring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bihlet, Asger Reinstrup, Kosalaram Goteti, Jesper Sonne, et al.. (2024). Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis. ACR Open Rheumatology. 6(4). 205–213. 9 indexed citations

Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet Neurology. 23(11). 1119–1132. 32 indexed citations

Montalbán, Xavier, Karolina Piasecka‐Stryczynska, Jens Kühle, et al.. (2024). Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Multiple Sclerosis Journal. 30(4-5). 558–570. 8 indexed citations

Pereira, Joao N.S., et al.. (2024). Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker. Journal of Pharmacokinetics and Pharmacodynamics. 52(1). 8–8.

Briat, Arnaud, C. Jacques, L. Sudre, et al.. (2022). 99mTc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model. Scientific Reports. 12(1). 8146–8146. 6 indexed citations

Stewart, Suzanne, et al.. (2021). Recombinant fibroblast growth factor‐18 (sprifermin) enhances microfracture‐induced cartilage healing. Journal of Orthopaedic Research®. 40(3). 553–564. 11 indexed citations

Bay‐Jensen, Anne‐Christine, Angela A. Manginelli, M.A. Karsdal, et al.. (2021). A low repair endotype is predictive for response to FGF-18 treatment: data from the phase II oa forward study. Osteoarthritis and Cartilage. 29. S144–S144. 2 indexed citations

Hodgins, Diana, A.C. Marijnissen, Hans Guehring, et al.. (2021). Motion analysis using the gaitsmartTMsystem in the imi-approach cohort. Osteoarthritis and Cartilage. 29. S22–S24.

Kwoh, C. Kent, Hans Guehring, Aida Aydemir, et al.. (2020). Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints. Osteoarthritis and Cartilage. 28(6). 782–791. 14 indexed citations

10.

Eckstein, F., Marc C. Hochberg, Hans Guehring, et al.. (2020). Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study. Osteoarthritis and Cartilage. 28. S77–S78. 3 indexed citations

11.

Brett, Alan, M.A. Bowes, Philip G. Conaghan, et al.. (2020). Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study. Osteoarthritis and Cartilage. 28(11). 1432–1436. 18 indexed citations

12.

Guehring, Hans, et al.. (2019). Recombinant human FGF18 preserves depth-dependent mechanical inhomogeneity in articular cartilage. European Cells and Materials. 38. 23–38. 15 indexed citations

13.

Wirth, W., S. Maschek, C. Ladel, et al.. (2019). Structural progressor thresholds of femorotibial cartilage change over 1 to 4-years for different MRI orientations and contrasts – data from the osteoarthritis initiative. Osteoarthritis and Cartilage. 27. S315–S316. 2 indexed citations

14.

Strotmann, Rainer, Asger Reinstrup Bihlet, Jesper Sonne, et al.. (2018). Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects. Osteoarthritis and Cartilage. 26. S276–S277. 5 indexed citations

15.

Gigout, Anne, Hans Guehring, Dara Froemel, et al.. (2017). Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis and Cartilage. 25(11). 1858–1867. 102 indexed citations

16.

Bay‐Jensen, Anne‐Christine, Asger Reinstrup Bihlet, I. Byrjalsen, et al.. (2017). Elevated levels of CRPM, an inflammatory biomarker correlating with disease activity in RA, are prognostic of radiographic knee OA. Osteoarthritis and Cartilage. 25. S32–S32. 3 indexed citations

17.

Brenneis, Christian, Kerstin Kleinschmidt, M. Michaelis, et al.. (2016). Penalized linear discriminant analysis reveals divergent gait patterns in three surgically-induced OA models. Osteoarthritis and Cartilage. 24. S107–S108. 1 indexed citations

18.

Hernández, Paula, et al.. (2014). Intra‐articular injection of rhFGF‐18 improves the healing in microfracture treated chondral defects in an ovine model. Journal of Orthopaedic Research®. 32(5). 669–676. 50 indexed citations

19.

Gigout, Anne, S. Lindemann, & Hans Guehring. (2014). Sprifermin (rhfgf18) has an anabolic effect on human osteoarthritic chondrocytes involving fgfr3 and erk1/2 but not p38α and JNKS. Osteoarthritis and Cartilage. 22. S164–S164. 1 indexed citations

20.

Gigout, Anne, et al.. (2012). Recombinant human fibroblast growth factor-18 (rhFG18) promotes bovine articular chondrocyte proliferation and cartilage matrix production in vitro. Osteoarthritis and Cartilage. 20. S135–S135. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact